Metoprolol (versus unexposed) updated on 12-17-2024

Caesarean

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S17157
R71956		 Vaclavik, 2024 Caesarean section during pregnancy (anytime or not specified) population based cohort retrospective unexposed, disease free Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified 2.51 [2.35;2.68] -/1,651   -/252,856 - 1,651
ref
S13913
R54437		 Duan, 2018 Cesarean during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified 1.95 [1.56;2.43] C 139/324   104,203/374,391 104,342 324
ref
Total 2 studies 2.26 [1.77;2.89] 104,342 1,975
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Vaclavik, 2024Vaclavik, 2024 2.51[2.35; 2.68]-1,65159%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: unclear Duan, 2018Duan, 2018 1.95[1.56; 2.43]104,34232441%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 79% 2.26[1.77; 2.89]104,3421,9750.510.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.26[1.77; 2.89]104,3421,97579%NAVaclavik, 2024 Duan, 2018 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 2.26[1.77; 2.89]104,3421,97579%NAVaclavik, 2024 Duan, 2018 2 Tags Adjustment   - No  - No 2.26[1.77; 2.89]104,3421,97579%NAVaclavik, 2024 Duan, 2018 2 Indications Antihypertensive   - All hypertensions, any indications ...  - All hypertensions, any indications or not specified 2.26[1.77; 2.89]104,3421,97579%NAVaclavik, 2024 Duan, 2018 2 All studiesAll studies 2.26[1.77; 2.89]104,3421,97579%NAVaclavik, 2024 Duan, 2018 20.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 2.26[1.77; 2.89]104,3421,97579%NAVaclavik, 2024 Duan, 2018 20.510.01.0